Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells

Life Sciences

Volumn 152, Issue , 2016, Pages 190-198

  Mohammadi, Saeed ^a,b   Ghaffari, Seyed H ^a   Shaiegan, Mojgan ^b   Zarif, Mahin Nikougoftar ^b   Nikbakht, Mohsen ^a   Akbari Birgani, Shiva ^a   Alimoghadam, Kamran ^a   Ghavamzadeh, Ardeshir ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

Author keywords

Acute myeloid leukemia (AML); Curcumin; KG 1; Leukemic Stem Cell; Osteopontin; U937 cells

Indexed keywords

BETA CATENIN; CD123 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CTNNB1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; ONCOPROTEIN; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER STEM CELL; CELL ISOLATION; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENRICHMENT CULTURE; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; INTRACELLULAR SIGNALING; LEUKEMIA CELL; LEUKEMIA STEM CELL; MALE; MIDDLE AGED; MTT ASSAY; MYELOID LEUKEMIA CELL LINE; PRIMARY CELL CULTURE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; U937 CELL LINE; UPREGULATION; ACUTE MYELOID LEUKEMIA; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIGENS, CD34; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; BETA CATENIN; BONE MARROW CELLS; CELL LINE, TUMOR; CURCUMIN; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; NEOPLASTIC STEM CELLS; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; OSTEOPONTIN; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84964330699     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.04.003     Document Type: Article

References (47)

1. G.J. Roboz, and M. Guzman Acute myeloid leukemia stem cells: seek and destroy Expert. Rev. Hematol. 2 2009 663 672
2. R.B. Walter, F.R. Appelbaum, M.S. Tallman, N.S. Weiss, R.A. Larson, and E.H. Estey Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm Blood 116 2010 2420 2428
3. D. Bonnet, and J.E. Dick Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat. Med. 3 1997 730 737
4. A.M. Martelli, C. Evangelisti, F. Chiarini, and J.A. McCubrey The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients Oncotarget 1 2010 89 103
5. K. Eppert, K. Takenaka, E.R. Lechman, L. Waldron, B. Nilsson, P. van Galen, K.H. Metzeler, A. Poeppl, V. Ling, J. Beyene, A.J. Canty, J.S. Danska, S.K. Bohlander, C. Buske, M.D. Minden, T.R. Golub, I. Jurisica, B.L. Ebert, and J.E. Dick Stem cell gene expression programs influence clinical outcome in human leukemia Nat. Med. 17 2011 1086 1093
6. S.K. Nilsson, H.M. Johnston, G.A. Whitty, B. Williams, R.J. Webb, D.T. Denhardt, I. Bertoncello, L.J. Bendall, P.J. Simmons, and D.N. Haylock Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells Blood 106 2005 1232 1239
7. H. Rangaswami, A. Bulbule, and G.C. Kundu Osteopontin: role in cell signaling and cancer progression Trends Cell Biol. 16 2006 79 87
8. S. Vejda, K. Piwocka, S.L. McKenna, and T.G. Cotter Autocrine secretion of osteopontin results in degradation of I kappa B in Bcr-Abl-expressing cells Br. J. Haematol. 128 2005 711 721
9. S. Flamant, T. Kortulewski, A. Dugray, M.L. Bonnet, M. Guillier, F. Guilhot, J.H. Bourhis, W. Vainchenker, D. Tronik-Le Roux, and A.G. Turhan Osteopontin is upregulated by BCR-ABL Biochem. Biophys. Res. Commun. 333 2005 1378 1384
10. J.A. Powell, D. Thomas, E.F. Barry, C.H. Kok, B.J. McClure, A. Tsykin, L.B. To, A. Brown, I.D. Lewis, K. Herbert, G.J. Goodall, T.P. Speed, N. Asou, B. Jacob, M. Osato, D.N. Haylock, S.K. Nilsson, R.J. D'Andrea, A.F. Lopez, and M.A. Guthridge Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML Blood 114 2009 4859 4870
11. N. Shafee, S. Kaluz, N. Ru, and E.J. Stanbridge PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines Cancer Lett. 282 2009 109 115
12. H.K. Mikkola, C.G. Radu, and O.N. Witte Targeting leukemia stem cells Nat. Biotechnol. 28 2010 237 238
13. A.M. Martelli, C. Evangelisti, W. Chappell, S.L. Abrams, J. Basecke, F. Stivala, M. Donia, P. Fagone, F. Nicoletti, M. Libra, V. Ruvolo, P. Ruvolo, C.R. Kempf, L.S. Steelman, and J.A. McCubrey Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway Leukemia 25 2011 1064 1079
14. D.C. Hassane, M.L. Guzman, C. Corbett, X. Li, R. Abboud, F. Young, J.L. Liesveld, M. Carroll, and C.T. Jordan Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data Blood 111 2008 5654 5662
15. S.W. Lane, D.T. Scadden, and D.G. Gilliland The leukemic stem cell niche: current concepts and therapeutic opportunities Blood 114 2009 1150 1157
16. A.C. Bharti, N. Donato, S. Singh, and B.B. Aggarwal Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis Blood 101 2003 1053 1062
17. A. Shehzad, F. Wahid, and Y.S. Lee Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials Arch. Pharm. (Weinheim) 343 2010 489 499
18. S. Padhye, D. Chavan, S. Pandey, J. Deshpande, K.V. Swamy, and F.H. Sarkar Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry Mini-Rev. Med. Chem. 10 2010 372 387
19. D.M. Hossain, S. Bhattacharyya, T. Das, and G. Sa Curcumin: The multi-targeted therapy for cancer regression Front. Biosci. (Schol. Ed.) 4 2012 335 355
20. S. Mukherjee Nee Chakraborty, U. Ghosh, N.P. Bhattacharyya, R.K. Bhattacharya, S. Dey, and M. Roy Curcumin-induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity Mol. Cell. Biochem. 297 2007 31 39
21. M. Tomita, H. Kawakami, J.N. Uchihara, T. Okudaira, M. Masuda, N. Takasu, T. Matsuda, T. Ohta, Y. Tanaka, K. Ohshiro, and N. Mori Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells Int. J. Cancer 118 2006 765 772
22. A. Zekri, S.H. Ghaffari, M. Yaghmaie, M.A. Estiar, K. Alimoghaddam, M.H. Modarressi, and A. Ghavamzadeh Inhibitor of aurora kinase B induces differentially cell death and polyploidy via DNA damage response pathways in neurological malignancy: shedding new light on the challenge of resistance to AZD1152-HQPA Mol. Neurobiol. 53 2016 1808 1823
23. M. Momeny, R. Ghasemi, G. Valenti, M. Miranda, A. Zekri, G. Zarrinrad, S. Javadikooshesh, M. Yaghmaie, K. Alimoghaddam, A. Ghavamzadeh, and S.H. Ghaffari Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway Tumour Biol. 2015
24. R. Liersch, J. Gerss, C. Schliemann, M. Bayer, C. Schwoppe, C. Biermann, I. Appelmann, T. Kessler, B. Lowenberg, T. Buchner, W. Hiddemann, C. Muller-Tidow, W.E. Berdel, and R. Mesters Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients Blood 119 2012 5215 5220
25. Y.H. Lin, C.J. Huang, J.R. Chao, S.T. Chen, S.F. Lee, J.J. Yen, and H.F. Yang-Yen Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor Mol. Cell. Biol. 20 2000 2734 2742
26. G. Song, Y. Ming, Y. Mao, S. Bao, and G. Ouyang Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells Exp. Biol. Med. 233 2008 1537 1545
27. M.S. Kim, M.J. Park, E.J. Moon, S.J. Kim, C.H. Lee, H. Yoo, S.H. Shin, E.S. Song, and S.H. Lee Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells Cancer Res. 65 2005 686 691
28. S. Philip, and G.C. Kundu Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways J. Biol. Chem. 278 2003 14487 14497
29. H. Rangaswami, A. Bulbule, and G.C. Kundu Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation J. Biol. Chem. 279 2004 38921 38935
30. J. Felipe Rico, D.C. Hassane, and M.L. Guzman Acute myelogenous leukemia stem cells: from bench to bedside Cancer Lett. 338 2013 4 9
31. K.M. Nicholson, and N.G. Anderson The protein kinase B/Akt signalling pathway in human malignancy Cell. Signal. 14 2002 381 395
32. T.M. Tilli, V.F. Franco, B.K. Robbs, J.L. Wanderley, F.R. da Silva, K.D. de Mello, J.P. Viola, G.F. Weber, and E.R. Gimba Osteopontin-c splicing isoform contributes to ovarian cancer progression Mol. Cancer Res. 9 2011 280 293
33. J. Dai, L. Peng, K. Fan, H. Wang, R. Wei, G. Ji, J. Cai, B. Lu, B. Li, D. Zhang, Y. Kang, M. Tan, W. Qian, and Y. Guo Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells Oncogene 28 2009 3412 3422
34. P.L. Dahia, R.C. Aguiar, J. Alberta, J.B. Kum, S. Caron, H. Sill, D.J. Marsh, J. Ritz, A. Freedman, C. Stiles, and C. Eng PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies Hum. Mol. Genet. 8 1999 185 193
35. A. Aggerholm, K. Gronbaek, P. Guldberg, and P. Hokland Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders Eur. J. Haematol. 65 2000 109 113
36. S. Shankar, and R.K. Srivastava Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer Int. J. Oncol. 30 2007 905 918
37. L. Packer, S. Pavey, A. Parker, M. Stark, P. Johansson, B. Clarke, P. Pollock, M. Ringner, and N. Hayward Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN Carcinogenesis 27 2006 1778 1786
38. L. Ysebaert, G. Chicanne, C. Demur, F. De Toni, N. Prade-Houdellier, J.B. Ruidavets, V. Mansat-De Mas, F. Rigal-Huguet, G. Laurent, B. Payrastre, S. Manenti, and C. Racaud-Sultan Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis Leukemia 20 2006 1211 1216
39. B.W. Robertson, and M.A. Chellaiah Osteopontin induces beta-catenin signaling through activation of Akt in prostate cancer cells Exp. Cell Res. 316 2010 1 11
40. G.X. Zhang, Z.Q. Zhao, H.D. Wang, and B. Hao Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway World J. Gastroenterol. 10 2004 205 208
41. E.V. Ariztia, V. Subbarao, D.B. Solt, A.W. Rademaker, A.P. Iyer, and Z.N. Oltvai Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation Exp. Cell Res. 288 2003 257 267
42. H.P. Koeffler, R. Billing, A.J. Lusis, R. Sparkes, and D.W. Golde An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1) Blood 56 1980 265 273
43. D.C. Taussig, J. Vargaftig, F. Miraki-Moud, E. Griessinger, K. Sharrock, T. Luke, D. Lillington, H. Oakervee, J. Cavenagh, S.G. Agrawal, T.A. Lister, J.G. Gribben, and D. Bonnet Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction Blood 115 2010 1976 1984
44. M.L. Guzman, S.J. Neering, D. Upchurch, B. Grimes, D.S. Howard, D.A. Rizzieri, S.M. Luger, and C.T. Jordan Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells Blood 98 2001 2301 2307
45. R.S. Samant, D.W. Clark, R.A. Fillmore, M. Cicek, B.J. Metge, K.H. Chandramouli, A.F. Chambers, G. Casey, D.R. Welch, and L.A. Shevde Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation Mol. Cancer 6 2007 6
46. L.P. Kane, V.S. Shapiro, D. Stokoe, and A. Weiss Induction of NF-kB by the Akt/PKB kinase Curr. Biol. 1999 601 604
47. V. Baud, and M. Karin Is NF-kB a good target for cancer therapy? Hopes and pitfalls Nat. Rev. Drug Discov. 8 2009 33 40